Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03213977 | R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL | unknown | Phase 3 | 475 | Fujian Medical UniversityOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03650933 | A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients | unknown | Phase 3 | 360 | Nanjing Yoko Biomedical Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma(BELIEVE-01) | unknown | Phase 3 | 150 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 20 | University Medical Center GroningenOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05351346 | Genotype-guided Treatment in DLBCL | unknown | Phase 3 | 1,100 | Ruijin HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05479136 | 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy(DRARCH) | unknown | Phase 3 | 30 | Nicole HillOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 160 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05097443 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 130 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT00317096 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | unknown | Phase 3 | 319 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03777085 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 3 | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2019 | clinicaltrials |
| NCT02767674 | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | Phase 3 | 258 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT02354313 | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients(MCL0208) | unknown | Phase 3 | 300 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Feb 9, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | unknown | Phase 3 | 870 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 5 | Dec 19, 2017 | clinicaltrials |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | unknown | Phase 3 | 648 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03229616 | BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02871869 | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 2 / Phase 3 | 316 | Xinjiang Medical UniversityOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT03151044 | R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL | unknown | Phase 3 | 408 | FENG Ji-fengOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT03123718 | High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL | unknown | Phase 3 | 205 | Chonnam National University HospitalOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00209209 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL(MCLelderly) | unknown | Phase 3 | 570 | European Mantle Cell Lymphoma NetworkOTHER | 7 | Mar 7, 2017 | clinicaltrials |
| NCT01449344 | Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL((R-HAD)) | unknown | Phase 3 | 128 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 2 | Mar 7, 2017 | clinicaltrials |
| NCT02842931 | R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis | unknown | Phase 3 | 300 | National Research Center for Hematology, RussiaNETWORK | 1 | Jul 25, 2016 | clinicaltrials |
| NCT02777736 | CNS Prophylaxis in Diffuse Large B-cell Lymphoma(CLSG-CNS-001) | unknown | Phase 3 | 500 | Czech Lymphoma Study GroupOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT01933711 | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma | unknown | Phase 3 | 328 | University Hospital HeidelbergOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT02438501 | Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma(WUCC-NHL02) | unknown | Phase 3 | 166 | Di DengOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449252 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | unknown | Phase 3 | 120 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449265 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 160 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449278 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 120 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02531841 | High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma(MATRix) | unknown | Phase 3 | 250 | University Hospital FreiburgOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT02423837 | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma(BRiF) | unknown | Phase 3 | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | unknown | Phase 3 | 360 | European Mantle Cell Lymphoma NetworkOTHER | 3 | Sep 10, 2012 | clinicaltrials |
| NCT00846157 | Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients(NKCell) | unknown | Phase 3 | 276 | NKBio Co.Ltd.INDUSTRY | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00499018 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma(DLCL04) | unknown | Phase 3 | 399 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00774826 | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | unknown | Phase 3 | 534 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT01277172 | TREatment of degeNerative and Neoplastic Diseases With Rituximab(TREND) | unknown | Phase 2 / Phase 3 | 54 | Probiomed S.A. de C.V.INDUSTRY | 1 | Jan 14, 2011 | clinicaltrials |
| NCT00435955 | Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma | unknown | Phase 3 | 240 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Feb 16, 2007 | clinicaltrials |
| NCT00180882 | LMBA02 Protocol for Patients With a Burkitt Lymphoma | unknown | Phase 3 | 260 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 11, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Aug 22, 2024source: clinicaltrials